|
Aug 6
|
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
|
|
Jul 23
|
Top Midday Gainers
|
|
Jul 23
|
BC-Most Active Stocks
|
|
Jul 23
|
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
|
|
Jul 18
|
Sector Update: Health Care Stocks Softer Late Afternoon
|
|
Jul 18
|
Snowflake initiated, Chipotle upgraded: Wall Street's top analyst calls
|
|
Jul 17
|
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
|
|
Jun 28
|
Shareholders in Clearside Biomedical (NASDAQ:CLSD) are in the red if they invested five years ago
|
|
Jun 17
|
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
|
|
May 9
|
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
|
|
May 8
|
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
|
|
Mar 12
|
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025
|
|
Feb 24
|
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?
|
|
Feb 20
|
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
|
|
Jan 28
|
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
|
|
Jan 22
|
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
|
|
Aug 27
|
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
|
|
Jul 29
|
Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China
|
|
Jul 11
|
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board
|
|
Jun 27
|
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
|